ArticleBMC cancer2025

Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition.

Alina Goerg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.